128 related articles for article (PubMed ID: 9367867)
1. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation.
Gana-Weisz M; Haklai R; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
Biochem Biophys Res Commun; 1997 Oct; 239(3):900-4. PubMed ID: 9367867
[TBL] [Abstract][Full Text] [Related]
2. Dislodgment and accelerated degradation of Ras.
Haklai R; Weisz MG; Elad G; Paz A; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
Biochemistry; 1998 Feb; 37(5):1306-14. PubMed ID: 9477957
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
Egozi Y; Weisz B; Gana-Weisz M; Ben-Baruch G; Kloog Y
Int J Cancer; 1999 Mar; 80(6):911-8. PubMed ID: 10074926
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
Khwaja A; Sharpe CC; Noor M; Kloog Y; Hendry BM
Kidney Int; 2005 Aug; 68(2):474-86. PubMed ID: 16014024
[TBL] [Abstract][Full Text] [Related]
5. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
[TBL] [Abstract][Full Text] [Related]
6. Stringent structural requirements for anti-Ras activity of S-prenyl analogues.
Aharonson Z; Gana-Weisz M; Varsano T; Haklai R; Marciano D; Kloog Y
Biochim Biophys Acta; 1998 Feb; 1406(1):40-50. PubMed ID: 9545527
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid.
Marom M; Haklai R; Ben-Baruch G; Marciano D; Egozi Y; Kloog Y
J Biol Chem; 1995 Sep; 270(38):22263-70. PubMed ID: 7673206
[TBL] [Abstract][Full Text] [Related]
8. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.
Clarke HC; Kocher HM; Khwaja A; Kloog Y; Cook HT; Hendry BM
J Am Soc Nephrol; 2003 Apr; 14(4):848-54. PubMed ID: 12660318
[TBL] [Abstract][Full Text] [Related]
9. Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.
Elad G; Paz A; Haklai R; Marciano D; Cox A; Kloog Y
Biochim Biophys Acta; 1999 Dec; 1452(3):228-42. PubMed ID: 10590312
[TBL] [Abstract][Full Text] [Related]
10. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
[TBL] [Abstract][Full Text] [Related]
11. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y
Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334
[TBL] [Abstract][Full Text] [Related]
12. Novel Ras antagonist blocks human melanoma growth.
Jansen B; Schlagbauer-Wadl H; Kahr H; Heere-Ress E; Mayer BX; Eichler H; Pehamberger H; Gana-Weisz M; Ben-David E; Kloog Y; Wolff K
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14019-24. PubMed ID: 10570191
[TBL] [Abstract][Full Text] [Related]
13. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
Weisz B; Giehl K; Gana-Weisz M; Egozi Y; Ben-Baruch G; Marciano D; Gierschik P; Kloog Y
Oncogene; 1999 Apr; 18(16):2579-88. PubMed ID: 10353601
[TBL] [Abstract][Full Text] [Related]
14. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y
Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255
[TBL] [Abstract][Full Text] [Related]
15. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
16. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth.
Marciano D; Ben-Baruch G; Marom M; Egozi Y; Haklai R; Kloog Y
J Med Chem; 1995 Apr; 38(8):1267-72. PubMed ID: 7731012
[TBL] [Abstract][Full Text] [Related]
17. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis.
Karussis D; Abramsky O; Grigoriadis N; Chapman J; Mizrachi-Koll R; Niv H; Kloog Y
J Neuroimmunol; 2001 Nov; 120(1-2):1-9. PubMed ID: 11694313
[TBL] [Abstract][Full Text] [Related]
18. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
19. Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells.
Yue W; Wang J; Li Y; Fan P; Santen RJ
Int J Cancer; 2005 Dec; 117(5):746-54. PubMed ID: 15957161
[TBL] [Abstract][Full Text] [Related]
20. 6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
Zhao Y; Fan D; Ru B; Cheng KW; Hu S; Zhang J; Li ET; Wang M
Eur J Cancer; 2016 Nov; 68():38-50. PubMed ID: 27710830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
